cannabis and painmarylanddo.org/wp-content/uploads/2018/09/...cannabis in painful hiv-associated...
Post on 11-Jul-2020
2 Views
Preview:
TRANSCRIPT
CANNABISANDPAIN
DebraKimless,M.D.MedicalDirector,ForwardGro
MAOPAnnualMeetingSeptember14,2018
FDA APPROVAL: PREGABALIN, DULOXETINE, MILNACIPRAN FOR FIBROMYALGIA PREGABALIN, DULOXETINE FOR NEUROPATHIC PAIN ALL OTHER RECOMMENDED MEDICINES ARE OFF-LABEL USE
HOW SUCCESSFUL ARE THESE MEDICATIONS? 50% People treated with PREGABALIN experienced a 30% reduction in pain versus placebos that experienced 19% reduction in pain. People treated with DULOXETINE experienced 49% reduction in pain as compared with placebo that received 32% reduction in pain A larger number of patients using MILNACIPRAN (25%) than placebo (19%) had at least a 30% reduction in pain
SIDE EFFECTS:
DULOXETINE : asthenia,constipation,diarrhea,dizziness,drowsiness,fatigue,hypersomnia,insomnia,nausea,sedation,headache,andxerostomia.Othersideeffectsinclude:agitation,erectiledysfunction,nervousness,psychomotoragitation,tension,vomiting,abdominalpain,anorexia,decreasedappetite,decreasedlibido,hyperhidrosis,abnormalorgasm,suicide
PREGABALIN : infection, ataxia, blurred vision, constipation, diplopia, dizziness, drowsiness, fatigue, headache, peripheral edema, tremor, weight gain, visual field loss, accidental injury, and xerostomia. Other side effects include: abnormal gait, abnormality in thinking, amnesia, arthralgia, asthenia, cognitive dysfunction, confusion, edema, neuropathy, sinusitis, speech disturbance, vertigo, visual disturbance, myasthenia, amblyopia, increased appetite, and twitching, disorientation, confusion, anxiety, serotonin syndrome in combo with SSRI’s
MILNACIPRAN : hypertensive crisis, constipation, dizziness, headache, hot flash, nausea, and insomnia. Other side effects include: hypertension, increased heart rate, migraine, palpitations, skin rash, vomiting, anxiety, increased pulse, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, hyperhidrosis, and xerostomia
UnitedStates,inparticular,acetaminophenaccountsformorethan50%ofoverdose-relatedacuteliverfailure
National Overdose Deaths Number of Deaths Involving All Drugs
63,632
72,306
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000 TotalFemaleMale
Source:NationalCenterforHealthStatistics,CDCWonder
AVERAGEERVISITCOSTS$1917
2MILLIONDOLLARSPERDAY!!!!!!
Biochemical Mechanisms of Pain Control by Cannabinoids (endogenous or exogenous) • Serotonergic• Dopaminergic• Anti-inflammatory• Cannabinoid-OpioidInteractions• PeriaqueductalGrayMatter• NMDA/GlutamateReceptors• SubstanceP• Synergy/EntourageEffect
MULTI-MODALMECHANISMSFORMODULATINGPAIN
21
• The ECS is active in tonic fashion in control of pain
• ECS functions in nociceptive areas of CNS
• Integrative control of pain in PAG
• VPL where CBs 10-fold more potent than morphine in WDR neurons mediating pain
MULTI-MODAL MECHANISMS FOR MODULATING PAIN
22
• ECS active in spinal cord pain mechanisms including NMDA, wind-up, and allodynia
• ECS also active in periphery on pain, inflammation, hyperalgesia
• Homeostasis of Activators and Sensitizers
through both CB1 and CB2
Analgesic and Anti-inflammatory Compounds in Cannabis
• Tetrahydrocannabinol(THC)• Cannabidiol(CBD)• Tetrahydrocannabinolicacid(THCA)• Cannabidiolicacid(CBDA)• BetaCaryophyllene• Plusmanyothers
23
CANNABINOID-OPIOIDSYNERGY
• Both produce analgesia through a G-protein-coupled mechanism that blocks the release of pain-propagating neurotransmitters in the brain and spinal cord
• Cannabinoids may interact with delta and kappa receptors
• Adding a cannabinoid to opioid therapy may lead to greater pain relief at lower opioid doses and less adverse effects
24
Cannabinoids – Mechanisms of action are distinct from opioids • THCandCBDhaveanalgesicefficacyinanimalmodels• MechanismsareduetoactivityatCB1andCB2receptors(THC),andatTRPV1receptors(CBD).• CBDhasanti-inflammatorypropertiesinvitro• Opioidefficacyrelatedtoactivityatmuopioidreceptors• CBreceptorsarescarceincardiorespiratorycentresincontrasttoopioidreceptorsSONOOVERDOSEDEATHSFROMCARDIORESPIRATORYARREST!!!!!
BUT• Cannabinoidsenhancereleaseofendogenousopioids• CBreceptorsmayco-localisewithmuopioidreceptorsANDNoevidenceofclinicallyrelevantadversedrug-druginteractionbetweencannabinoidsandopioids
IBUPROFEN: 636mg/kg CAFFEINE :192mg/kg NICOTINE: 50 mg/kg HEROIN: 22 mg/kg Itwouldtakea70kgmantosmoke1,500lbsina15minutestimeperiodtodie FrancisL.Young,AdministrativeLawJudgefortheUSDrugEnforcementAdministration(DEA)wroteinhisSep.6,1988decisioninacaseattemptingtoreschedulemarijuanasothatitcanbeprescribedbyphysicians:
LD 50
Potential Warnings with Cannabis use:
TACHYCARDIA HTN SOMNOLENCE HYPEREMESIS EUPHORIA ALTERED TIME PERCEPTION/PARANOIA, HALLUCINATIONS TOLERANCE
Empirical Medicine of the 19th Century • Combinedmorphine,cannabis,andcapsicum• Providedaphyto-opioid,phytocannabinoid,andphytovanilloidinonepreparation
• Affectedthe3knownendogenousbiochemicalsystemsmediatingpain:endorphin/enkephalin,endocannabinoid,vanilloid
• Arguablymayhaveprovidedbetteroutpatientpainreliefthaniscurrentlyavailableinthe21stcentury
• 19thcenturyphysiciansnotedabilityofcannabistoproduceopiatesparing,reducemorbidity,andtreatopiatewithdrawal
EBR
NationalAcademiesofSciences,Engineering,andMedicine:HealthandMedicineDivision2017Report,440pagesFulltextavailablefree:https://www.nap.edu/download/24625
Thereisconclusiveorsubstantialevidencethatcannabisorcannabinoidsareeffective:
• Forthetreatmentofchronicpaininadults(cannabis)(4-1)
• Asanti-emeticsinthetreatmentofchemotherapy-inducednauseaandvomiting(oralcannabinoids)(4-3)
• Forimprovingpatient-reportedmultiplesclerosisspasticitysymptoms(oralcannabinoids)(4-7a)
Thereismoderateevidencethatcannabisorcannabinoidsareeffectivefor:
• Improvingshort-termsleepoutcomesinindividualswithsleepdisturbanceassociatedwithobstructivesleepapneasyndrome,fibromyalgia,chronicpain,andmultiplesclerosis(cannabinoids,primarilynabiximols)(4-19)
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS) , Mark Ware et al, Journal of Pain December 2015. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) inthe treatment of pain caused by rheumatoid arthritis D. R. Blake et al, Rheumatology, 2006. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis, David J. Rog et al, Neurology, 2005. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial, D. Abrams et al., Neurology, 2007. Given the choice, patients will reach for cannabis over prescribed opioids, University of British Columbia, 2017
CANNABIS FOR PAIN
Noyes, R., Jr., Brunk, S. F., Avery, D. A. H., & Canter, A. C. (1975). The analgesic properties of
delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther, 18(1), 84-89.
WHATABOUTCBD????
CBD1. ISTHESECONDMOSTABUNDANTCANNABINOID2. CONSIDEREDNON-INTOXICATING3. HASAMULTI-MODALMECHANISMOFACTION4. CURRENTLY,SCIENCEIDENTIFIEDMORETHAN65MOLECULAR
TARGETS5. STILLBEINGINVESTIGATED
CBD
• DOESN’TBINDTOCB1ORCB2RECEPTORS• MODULATESNON-CANNABINOIDRECEPTORSANDIONCHANNELS• ACTSTHROUGHRECEPTOR-INDEPENDENTPATHWAYS
CBDANDNON-CANNABINOIDRECEPTORS
1. ACTIVATES5-HT1ASERATONINRECEPTORS:FORANTI-ANXIETY
ADDICTIONMITIGATION,APPETITEMODULATION,SLEEP,PAIN,NAUSEAANDVOMITING2.TRPV1VANILLOID(CAPSAICIN)RECEPTORS:MEDIATESPAINPERCEPTION,INFLAMMATION,TEMPERATUREREGULATION3.GPR55RECEPTOR:CBDISANANTAGONIST.MODULATESBP,ANDBONEDENSITY(INHIBITSOSTEOCLASTFUNCTION),INHIBITSCANCERCELLPROLIFERATION
CBDANDNON-CANNABINOIDRECEPTORS(continued)
4.PPAR(peroxisomeproliferatoractivatedreceptors)CBDISANAGONISTWHICHHASACANCERCELLANTI-PROLIFERATIVEEFFECT,INDUCESTUMORREGRESSIONINSOMECANCERS,MAYDEGRADEAMYLOID-BETAPLAQUE,MODULATESMETABOLISMANDMAYPLAYAROLEINDIABETES(MAYREDUCEINSULINRESISTENCE)
REUPTAKEINHIBITOR
1. RECENTLYREPORTED:FABPsESCORTENDOCANNABINOIDSINTOACELL
2. ONCEINSIDETHECELLECGETBROKENDOWN
3. CBDCOMPETESFORFABPsallowingformorecirculatingEC
ThisisthoughttobethemechanismofactionforCBDandBrainProtection,anti-seizure.
REUPTAKEINHIBITOR(continued)
1. ADENOSINEREUPTAKEINHIBITORBYCBDWHICHINCREASESBRAINADENOSINELEVELS.
2.CONFERSANTI-INFLAMMATORY/ANTI-ANXIETYEFFECTS,ALONGWITHCARDIOVASCULARFUNCTION.
ALLOSTERICMODULATOR
1. POSITIVE:ONTHEGABARECEPTOR,WHICHAMPLIFIESANXIOLYTICEFFECTSOFGABA2.NEGATIVE:ONTHECB1RECEPTOR,MODULATESTHEINTOXICATINGEFFECTSOFTHC
WHAT WOULD NIDA DO?
November09,2017
WEIGHINGRISKSV.BENEFITSWHICHDOYOUCHOOSE?
top related